FDA Acknowledges Astellas Pharma's Resubmission Of BLA For Zolbetuximab
31/5 05:07
(RTTNews) - The U.S. Food and Drug Administration has acknowledged Astellas Pharma's resubmission of the Biologics License Application (BLA) for zolbetuximab, a first-in-class investigational claudin (CLDN) 18.2-targeted monoclonal antibody, for the first-line treatment of adults...